To The Moon

The Case for Novo Nordisk at a Distressed Multiple

Novo Nordisk has had the sort of year that makes investors check their portfolios twice just to confirm the numbers are real. The shares have collapsed from a 52-week high of 81.44 to the mid-40s, sentiment has deteriorated sharply, and a company once treated like Europe’s growth crown jewel is now trading at barely 10–11 times earnings.

That disconnect is exactly why I think the opportunity has become so compelling.

Markets see collapse. The fundamentals suggest strategic transformation

The market is behaving as though Novo’s growth engine has permanently stalled. I believe something very different is happening: the company is transitioning from a blockbuster obesity story into a broader cardiometabolic platform, while simultaneously opening a new phase of GLP-1 adoption through oral therapies. Those are not signs of a fading franchise. They are signs of a business entering its next commercial era.

The Market Is Pricing Novo Like a Declining Business

The most striking feature of $Novo-Nordisk A/S(NVO)$ today is not the share-price decline itself. It is the valuation attached to a business still generating extraordinary profitability.

Operating margins remain above 61%. Profit margins sit above 37%. Return on equity is an enormous 71.4%, while quarterly revenue growth remains above 24% year-on-year. Those are elite numbers by almost any standard in global healthcare.

Yet the stock trades near 10–11 times earnings, dramatically below both its historical valuation and much of the wider pharmaceutical sector.

Markets rarely hand out discounts like this without reason. Investors are worried about pricing pressure in the US, intensifying competition from $Eli Lilly(LLY)$ and Company, political scrutiny around obesity drugs, and the possibility that the GLP-1 market becomes commoditised faster than expected.

Some of those fears are legitimate.

Novo’s balance sheet is not spotless. Total debt exceeds 146B, the current ratio sits below 1, and levered free cash flow has turned negative as the company spends aggressively on manufacturing expansion. That matters because GLP-1 dominance is no longer simply a pharmaceutical race; it is increasingly a supply-chain arms race. A company can possess the world’s best obesity therapy, but if it cannot manufacture enough doses, investors quickly discover that biology and logistics are very different disciplines.

At the same time, the stock’s ownership profile still suggests institutional investors largely view this as a fundamentally durable franchise rather than a collapsing speculative story. Short interest remains remarkably modest despite the share-price decline, which tells me the market is cautious on growth expectations but not aggressively betting against the underlying business itself.

Still, I think the market has moved from caution into outright overcorrection. Novo is being priced less like a category leader and more like a mature business entering structural decline. The underlying numbers simply do not support that interpretation.

The selloff now resembles capitulation more than structural deterioration

The Oral Pill Is Not Cannibalisation — It Is Market Expansion

This, to me, is the most misunderstood part of the Novo story.

The original fear surrounding oral Wegovy was straightforward: patients would abandon injectable therapies, margins would weaken, and Novo would cannibalise its own blockbuster franchise.

The Q1 2026 data suggests something far more significant is occurring.

Roughly 80% of oral Wegovy users were GLP-1 treatment-naive. That single statistic changes the investment debate entirely because it implies Novo is not merely reshuffling existing patients between delivery methods. It is unlocking an entirely new treatment population.

The scale of that opportunity is enormous.

Obesity has always suffered from a strange contradiction: hundreds of millions of people qualify medically for treatment, yet only a tiny percentage ever pursue advanced pharmaceutical intervention. Cost matters, of course, but so does psychology. Many patients simply never wanted injectable therapy, regardless of efficacy. Weekly injections created a behavioural ceiling on adoption that investors underestimated for years.

The pill format lowers that barrier dramatically.

That is why I think the oral rollout represents a market expansion event rather than a product extension. Novo is widening the top of the funnel, not merely defending share within it.

The pricing strategy reinforces that thesis. At roughly $149–$299 per month in a self-pay structure, Novo appears focused on maximising accessibility and patient onboarding rather than extracting peak short-term pricing. If that reading is correct, the strategic logic is powerful because obesity treatment increasingly resembles a long-duration ecosystem business. The company that captures the largest patient base early gains advantages in physician familiarity, adherence data, insurance negotiations, and eventually cross-selling into adjacent cardiometabolic therapies.

In other words, Novo may be willing to trade some pricing power today for stronger platform positioning tomorrow.

The prescription growth already hints at that potential. Weekly scripts reportedly reached around 207,000 by week 15, materially outpacing rival oral launches at similar stages. Investors still seem to be treating this as a defensive product cycle when it may actually represent the beginning of the next adoption curve.

Novo’s Real Business Is Becoming Much Bigger Than Weight Loss

Most investors still think of Novo primarily through the lens of Ozempic and Wegovy. I increasingly think that framing is outdated.

The more important story may be that Novo is constructing a full-scale cardiometabolic platform spanning obesity, diabetes, cardiovascular disease, kidney disease, and heart failure. That distinction is critical because platform businesses are valued differently from single-product franchises.

A blockbuster drug can fade. A therapeutic ecosystem becomes much harder to displace.

Semaglutide’s expansion into chronic kidney disease and heart failure with preserved ejection fraction is therefore strategically important beyond the immediate revenue opportunity. These conditions overlap heavily with obesity and diabetes, allowing Novo to deepen its relevance across the entire patient journey rather than operating as a one-product obesity specialist.

There is also a subtle healthcare-economics advantage here that the market may be underestimating. Payers are more likely to support reimbursement when obesity drugs begin demonstrating downstream cardiovascular and renal savings. Once therapies reduce hospitalisations, dialysis risk, or heart-failure complications, the economic conversation changes materially.

That could become one of the defining valuation shifts of the next decade.

Meanwhile, the next major catalyst is approaching quickly. CagriSema’s REDEFINE 1 data already showed 22.7% mean weight loss at 68 weeks, with more than 40% of participants achieving at least 25% weight reduction. Those are extraordinarily powerful outcomes, edging obesity treatment closer to bariatric-surgery territory than traditional pharmaceuticals.

Momentum weakens first. Narrative shifts usually arrive later

The full REDEFINE presentation at the ADA conference in June 2026 now matters enormously. Positive data would not merely reinforce Novo’s obesity leadership; it could materially reshape investor expectations around the company’s post-Wegovy growth runway.

Frankly, I suspect the market is still mentally valuing Novo as 'the Ozempic company' when management increasingly appears to be building something far broader.

Novo may be evolving from blockbuster drugmaker into healthcare infrastructure

My Verdict

Novo Nordisk no longer looks like the invincible momentum stock investors chased two years ago. Ironically, that is exactly why I find it more interesting today.

The valuation has compressed to levels that imply stagnation, yet the company continues to produce elite profitability, expand into new therapeutic categories, and unlock entirely new patient populations through oral GLP-1 adoption.

For me, the re-rating thesis ultimately depends on two things happening simultaneously: the market recognising that Novo’s current profitability metrics do not resemble a structurally impaired business, and investors beginning to value the company less as a single obesity-drug story and more as a long-duration cardiometabolic platform.

There are real risks here. Eli Lilly continues to pressure Novo on efficacy leadership, US drug-pricing negotiations remain a long-term margin threat, and manufacturing expansion leaves little room for operational mistakes. This is not a low-volatility recovery story wrapped neatly in Scandinavian packaging.

But I believe the market has become excessively focused on the slowing of the first GLP-1 boom while underestimating the scale of what Novo may become next.

The key moment to watch now is the ADA conference in June 2026. If the full CagriSema data reinforces early efficacy trends while oral Wegovy prescriptions continue expanding the treatment funnel, investors may start viewing Novo less as a fading obesity trade and more as a platform business temporarily trading at a distressed multiple.

And if that narrative shifts, the current valuation may eventually look less like a warning sign and more like a gift wrapped in temporary panic.

@TigerStars @Daily_Discussion @Tiger_comments @Tiger_SG @Tiger_Earnings @TigerClub @TigerWire